Investment Analysts’ Weekly Ratings Changes for BioMarin Pharmaceutical (BMRN)

Several brokerages have updated their recommendations and price targets on shares of BioMarin Pharmaceutical (NASDAQ: BMRN) in the last few weeks:

• 8/11/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d)”.
• 8/10/2026 – BioMarin Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $111.00 to $114.00. They now have a “buy” rating on the stock.
• 8/8/2026 – BioMarin Pharmaceutical was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – BioMarin Pharmaceutical had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $97.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – BioMarin Pharmaceutical had its price target raised by Morgan Stanley from $119.00 to $124.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – BioMarin Pharmaceutical had its price target raised by HC Wainwright from $50.00 to $60.00. They now have a “neutral” rating on the stock.
• 7/16/2026 – BioMarin Pharmaceutical had its price target raised by Citigroup Inc. from $75.00 to $76.00. They now have a “buy” rating on the stock.
• 7/14/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by UBS Group AG.
• 7/14/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright.
• 7/7/2026 – BioMarin Pharmaceutical had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have a “sector perform” rating on the stock.
• 6/26/2026 – BioMarin Pharmaceutical was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 6/22/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.